Cited by 130Pluripotent Stem Cells ResearchDevelopmental Biology and Gene RegulationCancer Cells and Metastasis

SALL4, the missing link between stem cells, development and cancer

Open access
Tatetsu, Hiro, Kong, Nikki R., Chong, Gao, Amabile, Giovanni, Tenen, Daniel G., Chai, Li·2016·Gene

Abstract

There is a growing body of evidence supporting that cancer cells share many similarities with embryonic stem cells (ESCs). For example, aggressive cancers and ESCs share a common gene expression signature that includes hundreds of genes. Since ESC genes are not present in most adult tissues, they could be ideal candidate targets for cancer-specific diagnosis and treatment. This is an exciting cancer-targeting model. The major hurdle to test this model is to identify the key factors/pathway(s) within ESCs that are responsible for the cancer phenotype. SALL4 is one of few genes that can establish this link. The first publication of SALL4 is on its mutation in a human inherited disorder with multiple developmental defects. Since then, over 300 papers have been published on various aspects of this gene in stem cells, development, and cancers. This review aims to summarize our current knowledge of SALL4, including a SALL4-based approach to classify and target cancers. Many questions about this important gene still remain unanswered, specifically, on how this gene regulates cell fates at a molecular level. Understanding SALL4's molecular functions will allow development of specific targeted approaches in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gene.2016.02.019

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SALL4 is re-expressed in a significant fraction of almost all human adult tumors.

    “As a transcription factor, the uniqueness of SALL4 lies in the fact that it is expressed in embryonic cells, downregulated during development, absent in most adult tissues, and re-expressed in a significant fraction of almost all human adult tumors (Moein et al, 2022; Tatetsu et al, 2016).”

    From Targeting transcription factors through an IMiD independent zinc finger domain (2025) · cites this paper as Tatetsu et al, 2016

    Section 3, “SALL4 in cancers” (page not provided), reports aberrant SALL4 expression in various cancers and re-expression in a subgroup of hepatocellular carcinoma patients. It does not establish that a significant fraction of almost all human adult tumors re-express SALL4; the section also says expression is rare in epithelioid sarcomas. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Re-expression of SALL4 in different cancer types was mostly associated with increased tumor cell proliferation and decreased patient survival.

    “Mostly, the re-expression of SALL4 was associated with increased tumor cell proliferation and decreased patient survival.”

    From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [26]

    Section 3 reports aberrant SALL4 expression across cancers and links SALL4 expression to poor survival in MDS and poor prognosis in HCC. The References list studies associating SALL4 with cancer-cell proliferation in breast and lung cancer. The copy does not establish that both associations hold for most cancer types in which SALL4 is re-expressed. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • SALL4 is absent in most adult tissues.

    “As a transcription factor, the uniqueness of SALL4 lies in the fact that it is expressed in embryonic cells, downregulated during development, absent in most adult tissues, and re-expressed in a significant fraction of almost all human adult tumors (Moein et al, 2022; Tatetsu et al, 2016).”

    From Targeting transcription factors through an IMiD independent zinc finger domain (2025) · cites this paper as Tatetsu et al, 2016

  • SALL4 aberrant re-expression has been reported for an increasing number of cancer types, such as germ cell tumors, hepatocellular carcinoma, gastric cancer, and leukemia.

    “its aberrant re-expression has been reported for an increasing number of cancer types, such as germ cell tumors, hepatocellular carcinoma, gastric cancer, leukemia-, and others26”
  • Sall4 is crucial for early embryo development, and mice without Sall4 cannot survive beyond E6.5.

    “Of note, Sall4 is crucial for the early development of embryos, and mice without Sall4 cannot survive beyond E6.540–42.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

7 of the 152 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Tatetsu, H., Kong, N. R., Chong, G., Amabile, G., Tenen, D. G., & Chai, L.
Affiliations
  • Brigham and Women's Hospital (US)
  • Adienne (Switzerland) (CH)
  • Harvard University (US)
Corresponding author
Chai, Li
Venue
Gene
Publisher
Elsevier BV
Published
2016-06
Volume
584
Issue
2
Pages
111-119
ISSN
0378-1119 (ISSN-L)
OpenAlex
W2274155363
Cited by
130
References
152
Citations by year
2026: 5 · 2025: 15 · 2024: 9 · 2023: 20 · 2022: 12 · 2021: 24 · 2020: 13 · 2019: 9 · 2018: 11 · 2017: 8 · 2016: 3 · 2014: 1
FWCI
0.94
Type
journal article
Language
en
Open access
Locations
  • Gene (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (GM089820, P01HL095489, R03CA184531)
  • Ministry of Education - Singapore
  • V Foundation for Cancer Research
  • Leukemia and Lymphoma Society (SLP-8004-14, TRP-6482-16)
  • National Research Foundation
  • National Medical Research Council
  • Ministry of Health -Singapore
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
SALL4, embryonic stem cells, cancer stem cells, carcinogenesis, cancer classification, targeted cancer therapy, cell fate regulation, developmental defects, gene expression signatures
MeSH terms
Humans, Neoplasms, Stem Cells, Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review